Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Bone grafts can be engineered by differentiating human mesenchymal stromal cells (MSCs) via the endochondral and intramembranous ossification pathways. We evaluated the effects of each pathway on the properties of engineered bone grafts and their capacity to drive bone regeneration. Bone-marrow-derived MSCs were differentiated on silk scaffolds into either hypertrophic chondrocytes (hyper) or osteoblasts (osteo) over 5 weeks of in vitro cultivation, and were implanted subcutaneously for 12 weeks. The pathways’ constructs were evaluated over time with respect to gene expression, composition, histomorphology, microstructure, vascularization and biomechanics. Hypertrophic chondrocytes expressed higher levels of osteogenic genes and deposited significantly more bone mineral and proteins than the osteoblasts. Before implantation, the mineral in the hyper group was less mature than that in the osteo group. Following 12 weeks of implantation, the hyper group had increased mineral density but a similar overall mineral composition compared with the osteo group. The hyper group also displayed significantly more blood vessel infiltration than the osteo group. Both groups contained M2 macrophages, indicating bone regeneration. These data suggest that, similar to the body’s repair processes, endochondral pathway might be more advantageous when regenerating large defects, whereas intramembranous ossification could be utilized to guide the tissue formation pattern with a scaffold architecture.

Details

Title
Effects of Endochondral and Intramembranous Ossification Pathways on Bone Tissue Formation and Vascularization in Human Tissue-Engineered Grafts
Author
Bernhard, Jonathan C 1 ; Darja Marolt Presen 2 ; Li, Ming 1 ; Monforte, Xavier 3 ; Ferguson, James 2 ; Leinfellner, Gabriele 2 ; Heimel, Patrick 4   VIAFID ORCID Logo  ; Betti, Susanna L 1   VIAFID ORCID Logo  ; Shu, Sharon 1 ; Teuschl-Woller, Andreas H 3   VIAFID ORCID Logo  ; Tangl, Stefan 5   VIAFID ORCID Logo  ; Redl, Heinz 2   VIAFID ORCID Logo  ; Vunjak-Novakovic, Gordana 6 

 Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA 
 Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA, 1200 Vienna, Austria; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria 
 Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria; Department of Life Science Engineering, University of Applied Sciences Technikum Wien, 1200 Vienna, Austria 
 Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA, 1200 Vienna, Austria; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria; School of Dentistry, Medical University of Vienna, 1090 Vienna, Austria 
 Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria; School of Dentistry, Medical University of Vienna, 1090 Vienna, Austria 
 Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA; Department of Medicine, Columbia University, New York, NY 10032, USA; College of Dental Medicine, Columbia University, New York, NY 10032, USA 
First page
3070
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20734409
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2724214748
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.